Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

18. Mai 2020 07:00 ET | Quelle: NuCana plc

NuCana Announces the Re-Opening of Enrollment in Multiple Clinical Studies After Temporary Pause Due to COVID-19 Pandemic

EDINBURGH, United Kingdom, May 18, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced it has re-commenced enrollment of new patients in multiple clinical studies following the temporary...
15. Mai 2020 07:00 ET | Quelle: NuCana plc

NuCana to Present Two Abstracts at the American Association for Cancer Research (AACR) Annual Meeting 2020

Non-Clinical Findings Suggest that Acelarin and NUC-3373 May Induce an Immune Response Against Cancer Cells Acelarin (NUC-1031) Releases DAMPs and Upregulates PD-L1 Expression in Lung Cancer Cells ...
05. Mai 2020 16:01 ET | Quelle: NuCana plc

NuCana Announces Re-Opening of Global Phase III Study of Acelarin Plus Cisplatin in Patients with Biliary Tract Cancer (NuTide:121)

EDINBURGH, U.K., May 05, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced it has re-commenced enrollment of new patients in NuTide:121, its ongoing global Phase III study of Acelarin...
02. April 2020 16:01 ET | Quelle: NuCana plc

NuCana Provides Update on Impact of COVID-19 on Clinical Studies

EDINBURGH, United Kingdom, April 02, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) has been closely monitoring the potential impact of the COVID-19 pandemic on its operations and announced...
10. März 2020 16:02 ET | Quelle: NuCana plc

NuCana Reports Fourth Quarter and Year-End 2019 Financial Results and Provides Business Update

First Patients Dosed in Global Phase III Biliary Tract Cancer Study (NuTide:121) with Potential for Accelerated Approval Filing Numerous Clinical Data Announcements Expected in 2020 Cash and Cash...
10. März 2020 16:01 ET | Quelle: NuCana plc

NuCana Reports Preliminary Data from Phase II Study of Single-Agent Acelarin (NUC-1031) in Patients with Platinum-Resistant Ovarian Cancer

Confirmed Complete Response and Two Partial Responses Achieved in Heavily Pre-treated Population Patients had Median of Five Prior Lines of Therapy EDINBURGH, United Kingdom, March 10, 2020 (GLOBE...
04. März 2020 07:00 ET | Quelle: NuCana plc

NuCana Receives Positive Opinion for Orphan Drug Designation in the European Union for Acelarin (NUC-1031) for the Treatment of Patients with Biliary Tract Cancer

EDINBURGH, United Kingdom, March 04, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced that the European Medicines Agency’s (EMA) Committee for Orphan Medicinal Products (COMP) has issued...
25. Februar 2020 07:00 ET | Quelle: NuCana plc

NuCana to Present at the Cowen and Company 40th Annual Health Care Conference

EDINBURGH, United Kingdom, Feb. 25, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Hugh Griffith, Chief Executive Officer, and Don Munoz, Chief Financial Officer, will...
27. Januar 2020 07:00 ET | Quelle: NuCana plc

NuCana Announces First Patients Dosed in Both US and Europe in Phase III Study of Acelarin (NUC-1031) for the First-Line Treatment of Patients with Biliary Tract Cancer

Global NuTide:121 Study Is Enrolling up to 828 Patients and Comparing Acelarin plus Cisplatin to Gemcitabine plus Cisplatin NuTide:121 Trials-in-Progress Poster Presented at ASCO-GI SAN FRANCISCO,...
26. November 2019 07:00 ET | Quelle: NuCana plc

NuCana to Participate in the Piper Jaffray 31st Annual Healthcare Conference

EDINBURGH, United Kingdom, Nov. 26, 2019 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) announced today that Don Munoz, Chief Financial Officer, will host one-on-one meetings at the Piper Jaffray...

Vorherige Seite

Nächste Seite